Shares of Spark Therapeutics Inc. (NASDAQ:ONCE) shot up 4.3% on Tuesday . The stock traded as high as $65.99 and last traded at $64.75, with a volume of 436,761 shares traded. The stock had previously closed at $62.09.

Several research firms have weighed in on ONCE. Jefferies Group reissued a “hold” rating on shares of Spark Therapeutics in a research report on Sunday, June 12th. Chardan Capital set a $35.00 price objective on shares of Spark Therapeutics and gave the company a “hold” rating in a report on Thursday, July 21st. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Spark Therapeutics in a report on Thursday, July 14th. Wedbush reaffirmed an “underperform” rating and issued a $29.00 price objective (up from $28.00) on shares of Spark Therapeutics in a report on Wednesday, August 10th. Finally, Zacks Investment Research raised shares of Spark Therapeutics from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a report on Thursday, August 11th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $62.27.

The stock’s market cap is $2.01 billion. The stock has a 50 day moving average price of $58.71 and a 200 day moving average price of $47.12.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/spark-therapeutics-inc-once-shares-up-4-3.html

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Wednesday, August 10th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by $0.07. Spark Therapeutics had a negative return on equity of 26.96% and a negative net margin of 366.76%. The company had revenue of $1.29 million for the quarter, compared to analyst estimates of $1.17 million. During the same period in the previous year, the business posted ($0.60) EPS. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. On average, analysts anticipate that Spark Therapeutics Inc. will post ($3.96) EPS for the current fiscal year.

In other news, insider Barge Joseph La sold 3,000 shares of Spark Therapeutics stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $52.24, for a total value of $156,720.00. Following the transaction, the insider now directly owns 8,325 shares of the company’s stock, valued at approximately $434,898. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Hospital Of Philade Children’s sold 1,000,000 shares of Spark Therapeutics stock in a transaction on Tuesday, August 16th. The shares were sold at an average price of $60.90, for a total transaction of $60,900,000.00. Following the completion of the transaction, the director now directly owns 5,768,707 shares in the company, valued at $351,314,256.30. The disclosure for this sale can be found here. Company insiders own 9.60% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Teacher Retirement System of Texas boosted its position in shares of Spark Therapeutics by 14.0% in the second quarter. Teacher Retirement System of Texas now owns 2,432 shares of the company’s stock worth $124,000 after buying an additional 299 shares during the last quarter. ProShare Advisors LLC boosted its position in shares of Spark Therapeutics by 6.5% in the second quarter. ProShare Advisors LLC now owns 22,493 shares of the company’s stock worth $1,150,000 after buying an additional 1,372 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Spark Therapeutics by 105.6% in the second quarter. Legal & General Group Plc now owns 2,714 shares of the company’s stock worth $138,000 after buying an additional 1,394 shares during the last quarter. Tocqueville Asset Management L.P. boosted its position in shares of Spark Therapeutics by 4.1% in the second quarter. Tocqueville Asset Management L.P. now owns 50,650 shares of the company’s stock worth $2,590,000 after buying an additional 2,000 shares during the last quarter. Finally, BlackRock Group LTD boosted its position in shares of Spark Therapeutics by 92.6% in the first quarter. BlackRock Group LTD now owns 4,843 shares of the company’s stock worth $143,000 after buying an additional 2,328 shares during the last quarter. 78.79% of the stock is currently owned by institutional investors and hedge funds.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs).

5 Day Chart for NASDAQ:ONCE

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.